GB2357765A - Water-insoluble alginate sponge material - Google Patents
Water-insoluble alginate sponge material Download PDFInfo
- Publication number
- GB2357765A GB2357765A GB9924266A GB9924266A GB2357765A GB 2357765 A GB2357765 A GB 2357765A GB 9924266 A GB9924266 A GB 9924266A GB 9924266 A GB9924266 A GB 9924266A GB 2357765 A GB2357765 A GB 2357765A
- Authority
- GB
- United Kingdom
- Prior art keywords
- alginate
- composition
- foam
- water
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 111
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 111
- 229940072056 alginate Drugs 0.000 title claims abstract description 106
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title claims abstract description 105
- 239000000203 mixture Substances 0.000 claims abstract description 135
- 239000006260 foam Substances 0.000 claims abstract description 55
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 9
- 150000001768 cations Chemical class 0.000 claims abstract 10
- 229910052751 metal Inorganic materials 0.000 claims abstract 4
- 239000002184 metal Substances 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims description 65
- 206010052428 Wound Diseases 0.000 claims description 30
- 208000027418 Wounds and injury Diseases 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 18
- 229920002774 Maltodextrin Polymers 0.000 claims description 17
- 239000000047 product Substances 0.000 claims description 17
- 239000005913 Maltodextrin Substances 0.000 claims description 16
- 229940035034 maltodextrin Drugs 0.000 claims description 16
- 235000010413 sodium alginate Nutrition 0.000 claims description 16
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 15
- 239000000661 sodium alginate Substances 0.000 claims description 15
- 229940005550 sodium alginate Drugs 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 235000010410 calcium alginate Nutrition 0.000 claims description 14
- 239000000648 calcium alginate Substances 0.000 claims description 14
- 229960002681 calcium alginate Drugs 0.000 claims description 14
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000004615 ingredient Substances 0.000 claims description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 11
- 235000010323 ascorbic acid Nutrition 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 239000000835 fiber Substances 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 8
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 230000008901 benefit Effects 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 229910021538 borax Inorganic materials 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000004328 sodium tetraborate Substances 0.000 claims description 5
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 4
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 229910001424 calcium ion Inorganic materials 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims 62
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 20
- 238000003756 stirring Methods 0.000 claims 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 15
- 239000004094 surface-active agent Substances 0.000 claims 15
- 235000011054 acetic acid Nutrition 0.000 claims 14
- 229960000583 acetic acid Drugs 0.000 claims 13
- 239000008367 deionised water Substances 0.000 claims 13
- 229910021641 deionized water Inorganic materials 0.000 claims 12
- 239000007789 gas Substances 0.000 claims 12
- 235000011187 glycerol Nutrition 0.000 claims 10
- 239000004014 plasticizer Substances 0.000 claims 10
- -1 anion alginate Chemical class 0.000 claims 9
- 239000003242 anti bacterial agent Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000004744 fabric Substances 0.000 claims 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 9
- 229920000136 polysorbate Polymers 0.000 claims 9
- 229920000053 polysorbate 80 Polymers 0.000 claims 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 8
- 102000008186 Collagen Human genes 0.000 claims 8
- 108010035532 Collagen Proteins 0.000 claims 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 8
- 229920001436 collagen Polymers 0.000 claims 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 7
- 239000011777 magnesium Substances 0.000 claims 7
- 229910052749 magnesium Inorganic materials 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 6
- 239000002131 composite material Substances 0.000 claims 6
- 229910021645 metal ion Inorganic materials 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 239000000908 ammonium hydroxide Substances 0.000 claims 5
- 229940088710 antibiotic agent Drugs 0.000 claims 5
- 239000000017 hydrogel Substances 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 4
- 229920002245 Dextrose equivalent Polymers 0.000 claims 4
- 150000000996 L-ascorbic acids Chemical class 0.000 claims 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 4
- 229910052782 aluminium Inorganic materials 0.000 claims 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 4
- 229910052786 argon Inorganic materials 0.000 claims 4
- 235000011132 calcium sulphate Nutrition 0.000 claims 4
- 239000001569 carbon dioxide Substances 0.000 claims 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 4
- 238000010276 construction Methods 0.000 claims 4
- 229910052802 copper Inorganic materials 0.000 claims 4
- 239000010949 copper Substances 0.000 claims 4
- 238000005516 engineering process Methods 0.000 claims 4
- 239000000499 gel Substances 0.000 claims 4
- 235000012208 gluconic acid Nutrition 0.000 claims 4
- 235000014655 lactic acid Nutrition 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 4
- 239000011701 zinc Substances 0.000 claims 4
- 229910052725 zinc Inorganic materials 0.000 claims 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims 3
- 239000003570 air Substances 0.000 claims 3
- 229910052783 alkali metal Inorganic materials 0.000 claims 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims 3
- 150000008041 alkali metal carbonates Chemical class 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 235000010407 ammonium alginate Nutrition 0.000 claims 3
- 239000000728 ammonium alginate Substances 0.000 claims 3
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 claims 3
- 229910052788 barium Inorganic materials 0.000 claims 3
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 3
- 229960005188 collagen Drugs 0.000 claims 3
- 230000000536 complexating effect Effects 0.000 claims 3
- 239000006185 dispersion Substances 0.000 claims 3
- 238000005187 foaming Methods 0.000 claims 3
- 229910052742 iron Inorganic materials 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 235000011090 malic acid Nutrition 0.000 claims 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 3
- 229910052754 neon Inorganic materials 0.000 claims 3
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 claims 3
- 229910052700 potassium Inorganic materials 0.000 claims 3
- 239000011591 potassium Substances 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 3
- 159000000000 sodium salts Chemical class 0.000 claims 3
- 229910052712 strontium Inorganic materials 0.000 claims 3
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 229910052723 transition metal Inorganic materials 0.000 claims 3
- GDTSJMKGXGJFGQ-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound O1B([O-])OB2OB([O-])OB1O2 GDTSJMKGXGJFGQ-UHFFFAOYSA-N 0.000 claims 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000006285 cell suspension Substances 0.000 claims 2
- 238000007865 diluting Methods 0.000 claims 2
- 239000012362 glacial acetic acid Substances 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 239000004033 plastic Substances 0.000 claims 2
- 229920003023 plastic Polymers 0.000 claims 2
- 229920000728 polyester Polymers 0.000 claims 2
- 238000004080 punching Methods 0.000 claims 2
- 239000002002 slurry Substances 0.000 claims 2
- 230000001954 sterilising effect Effects 0.000 claims 2
- 239000012258 stirred mixture Substances 0.000 claims 2
- 108010001478 Bacitracin Proteins 0.000 claims 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 1
- 229920000742 Cotton Polymers 0.000 claims 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 claims 1
- 229930193140 Neomycin Natural products 0.000 claims 1
- 108010093965 Polymyxin B Proteins 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 229920000297 Rayon Polymers 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000002390 adhesive tape Substances 0.000 claims 1
- 229910052925 anhydrite Inorganic materials 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 229960003071 bacitracin Drugs 0.000 claims 1
- 229930184125 bacitracin Natural products 0.000 claims 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- 229940078495 calcium phosphate dibasic Drugs 0.000 claims 1
- 239000001175 calcium sulphate Substances 0.000 claims 1
- 238000009960 carding Methods 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229910052804 chromium Inorganic materials 0.000 claims 1
- 239000011651 chromium Substances 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000011888 foil Substances 0.000 claims 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims 1
- 239000000174 gluconic acid Substances 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- 230000002439 hemostatic effect Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 150000002433 hydrophilic molecules Chemical class 0.000 claims 1
- 239000011261 inert gas Substances 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 229960004927 neomycin Drugs 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229920000024 polymyxin B Polymers 0.000 claims 1
- 229960005266 polymyxin b Drugs 0.000 claims 1
- 235000010408 potassium alginate Nutrition 0.000 claims 1
- 239000000737 potassium alginate Substances 0.000 claims 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000002964 rayon Substances 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 150000003751 zinc Chemical class 0.000 claims 1
- 239000011667 zinc carbonate Substances 0.000 claims 1
- 235000004416 zinc carbonate Nutrition 0.000 claims 1
- 229910000010 zinc carbonate Inorganic materials 0.000 claims 1
- 238000009987 spinning Methods 0.000 abstract description 3
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000003352 sequestering agent Substances 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/48—Surfactants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/04—Alginic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The specification discloses an alginate foam composition dressing which may be prepared with or without a backing. The foam dressing exhibits unique capability in including soluble or insoluble medicaments as part of the alginate foam composition, attributes not inherent in alginate dressings prepared by spinning. The dressings so prepared also eliminate the need for adhesives and secondary dressings for retaining an alginate dressing on a wound site. The foam is formed by addition of a di- or trivalent metal cation to a solution of water-soluble alginate, followed by addition of a gaseous foam-forming or effervescent compound and an acid, then drying the foam.
Description
2357765 ALGINATE FOAM COMPOSITIONS U.S. Patent Number 5,718,916 issued to
Scherr describes in some detail the background of the use of alginates as well as their application in medical and veterinary medicine; said outline of the background data for the use of alginates as set forth in U.S.
Patent Number 5,718,916 in columns 1, 2, and column 3 to line 33, are incorporated herein by reference. 10 The U.S. Patent Number 5,718,916 more specifically deals with the preparation of a spongelike or foam alginate composition which requires lyophilization or freeze drying in order to remove the aqueous component of the composition and so results in 15 a foam product which has certain advantages over fiber-related alginates which are produced by a spinning process. An advantage of the invention described herein relates to the preparation of foam alginate 20 compositions in which the aqueous portion of the composition can be removed by air-drying or regulated heat drying without the necessity of utilizing an expensive freeze-drying apparatus so significantly reducing the cost of the final product as well as the 25 reduction in time of its preparation. In the U.S. Patent 5,718,916 for the preparation of alginate foam products, note that the examples 2 cited and many of the claims made, utilize a sequestering agent such as sodium citrate in order to delay the immediate precipitation of calcium alginate when calcium salts are added to a solution of sodium alginate. Since the sequestering agent does not permit too long an extended period of time prior to the alginate being precipitated as the calcium salt, the examples cited in U.S. Patent 5,718,916 clearly indicate that the composition has to be added to a dish or tray immediately after mixing prior to its being frozen and lyophilized.
It is thus another salient advantage of the invention described herein, that no sequestering agent is required and that the calcium alginate so formed permits a semi-solid gel to be poured into any receptacle even hours after it is formed without the restraints of having to immediately place it into a dish prior to its being dried by a suitable method.
The lack of a restraint of the element of time in preparing the calcium foam alginate composition as described herein makes feasible the adjustment of viscosity of the composition without the necessity to work quickly and freeze the mixture as is made necessary in U.S. Patent No. 5,718,916, prior to its being dried and prepared for use in medical or veterinary applications. Where it might be necessary to effect an adjustment of pH in the alginate foam 3 composition, the operator can also make such adjustments over the period of time necessary without the restraint of time that is inherent in the U.S.
Patent Number 5,718,916.
It is generally known in the profession that sodium alginate in aqueous solution is highly sensitive to precipitation by calcium ions and that even as low a concentration of 1 to 100,000 of sodium alginate in aqueous solution, can result in precipitation of calcium alginate in the presence of such solutions as calcium chloride. Since the calcium alginate foam composition prepared herein is highly viscous and would result in a viscosity that may be difficult to layer in a homogenous thin layer on a plate to permit its drying, it was discovered that the addition of ammonia in aqueous solution or ammonium salts would reduce the viscosity of the calcium alginate foam composition and significantly improve the ease with which the layering of the calcium alginate foam composition may be layered. Since, during the drying process, free ammonia is liberated from such a composition which has included the use of a solution of ammonia, the ammonia being liberated will then result in enhanced viscosity and concomitantly increase strengthening of the foam composition thus prepared by the removal of ammonia during the drying process.
4 The use of various dressings frequently require that they be very soft and amenable to being draped around fingers, arms, or legs where injury has occurred. Consequently, it is a desirable attribute of such dressings to be highly flexible and amenable to being easily draped without their surface being distorted by the stress of such draping. It has been discovered that the addition of a compound such as sodium tetraborate (borax) results in the calcium alginate foam composition which is highly flexible, has an increased elasticity, and can be readily draped around small circumferences such as a finger without distortion or breakage of the alginate dressing so formed.
1-5 Another salient advantage of the invention described herein concerns the feasibility of adding ingredients to the alginate composition, which ingredients may contain properties such as being particulate, having high viscosity, or having or resulting in a rheology which is undesirable in making it feasible for such compositions to be forced through a fine spinneret to produce the alginate fibers as currently practiced in the profession.
The use of desirable particulate matter such as microparticles that can act as time-release particles, aqueous insoluble medicaments, or even the use of intact cells such as yeast cells, blood cells, or human or animal tissue cells, that might be desirable to apply to an open wound may be introduced into the alginate foam composition described herein. As is well known in the profession the pH of the alginate composition may have to be adjusted to be commensurate with the cells that are to be incorporated in the final composition, and such pH adjustment is readily made by those skilled in the art. Such particulate matter and/or aqueous insoluble matter which can be incorporated into the alginate foam composition described in our patent is an attribute not feasible when calcium alginate fibers are prepared by a spinning process.
U. S. Patent Numbers 4, 778,679 and 5,177,065 deal with the treatment of wounds utilizing a starch hydrolyzate (a maltodextrin). Example 1 in U.S.
Patent Number 4,778,679 utilizes a starch hydrolyzate powder blended with approximately 5% ascorbic acid which is merely sprinkled as a powder onto an open wound or ulcer site which then must be covered with a dressing. Example 3 in U.S. Patent Number 4,778,679 also describes the use of such a maltodextrin, to which has been added sodium ascorbate, but again it is applied by sprinkling the powder onto an open wound or lesion. Example 6 in U.S. Patent Number 4,778,679 sprinkles a starch hydrolyzate to which has been added 5% ascorbic acid and a solution of multiple amino 6 acids. U.S. Patent Number 5,177,065 teaches the use of a starch hydrolyzate (maltodextrin) powder which is applied to an open wound and which ultimately hardens to form a hardened surface in and on the wound or lesion. In the same patent, (5,177,065) the authors find a need to increase the adherence of the starch
Claims (1)
- hydrolyzate powder composition (Claim 2) by adding other products to it,which might assist it in forming an adhesion to the wound in the form of a film, such as the use of various film forming agents.A typical application of the teachings of U.S.Patent Numbers 4,778,679 and 5,177,065 can be gleaned from the use of a maltodextrin wound dressing called Multidex,R which is manufactured by DeRoyal Industries, Inc. Said Multidex product is provided for the treatment of wounds in the form of a powder which is sprinkled on the wound and which then requires an appropriate dressing to hold the powder in place. DeRoyal Industries, Inc. also supplies maltodextrin wound dressing in the form of a gel which is squeezed from a foil packet onto a wound, but still requires a secondary dressing (the DeRoyal literature describing the Multidex Maltodextrin brand wound dressings are contained in their clinical reprint #0 825).Neither U.S. Patent Numbers 5,177,065 and 4,778,679, nor anyone in the profession has succeeded 7 in preparing a dressing which in and of itself will contain the starch hydrolyzate (maltodextrin) compositions described in the patents 5,177, 065 and 4,778,679 and in the commercial products of DeRoyal which can be packaged, sterilized, stored, and used directly on a wound at any appropriate time that is desired without the need to use amultiplicity of products and the awkward use of powders and ointments, which then require an additional dressing as described in the above literature. The alginate foam composition described herein serve as a unique matrix for the maltodextrin component.Having set forth the tenets of the invention contained herein, the following non-limiting examples illustrate various compositions that are inherent in our invention.EXAMPLE 1 Place 4000 ml of deionized water into a plastic container and, with stirring, slowly add 100 grams of Kelco HV brand of sodium alginate. The stirring should be sufficiently vigorous to form a vortex in the water so that the sodium alginate added to the water is directed into the middle of the vortex to ensure a very efficient dispersion of the alginate particles and so increase the rate of solution. The mixture is stirred until all of the sodium alginate has been dissolved.8 To 1125 ml of the 2.5% sodium alginate solution prepared as above, add the following ingredients: 15 grams of sodium bicarbonate (Na HC03), 75 ml of glycerin, ml of the surface active agent L64, (Wyandotte Corp.) 6.9 ml of the surface active agent Tween 80 After stirring vigorously for approximately ten minutes to ensure that all of the ingredients have been dispersed, add 100 ml of deionized water containing 45 grams of sodium tetraborate (Na2B407 10H20). After stirring for a few minutes to ensure that the borate solution has been thoroughly dispersed, add 33 ml of ammonium hydroxide (28% NH3) and 15 grams of polyethylene glycol (average MN CA 1000).While continuously stirring, slowly add 9 grams of calcium sulfate (CaS04. 2H.0) into the vortex of the alginate solution and then follow with 35 ml of a dilute solution of acetic acid prepared by diluting one part of glacial acetic acid with 2 parts of deionized water.The diluted acetic acid should be added very slowly with a pipette, again into the vortex of the stirred mixture, and vigorous stirring continued for approximately five minutes.Following the addition of the acetic acid, the composition will gradually become more viscous. One 9 should now add 1800 ml of deionized water.The alginate composition thus prepared will contain a considerable amount of foam, which foam will not rise to the surface of the alginate composition, because the viscosity of the final alginate composition is greater than the buoyancy of the foam. When poured onto a plate, such as one made of plastic or metal, the dish may be air-dried or placed into a drying oven on the following schedule of drying:703 C - 2 hours 603 C - 2 hours 403 C until dry Alternately, the alginate composition prepared as above can be poured onto a backing composed of a cotton-rayon mixture or a polyester non-woven backing, so that an amount of the alginate foam mixture penetrates into the fiber and thus when dry, will retain this backing as part of the dried finished dressing.The U.S. Patent Number 5,674,524 expressed novelty in that prior to said U.S. Patent, the manufacturers of alginate fiber dressings were obliged to recommend that, once the alginate fiber dressing is placed on a wound, then a secondary sterile dressing would have to be affixed on top of the alginate dressing prior to its being affixed in place with adhesive tapes. The U.S. Patent 5,674,524 resolved the laborious and expensive procedure for alginate dressings to require two separate sterile dressings to be affixed over a wound. This was resolved by utilization of needle punching of the alginate fiber dressing to a backing following the carding operation. It is a unique attribute of the patent described herein, that even needle punching is unnecessary to have the foam alginate composition affixed to a suitable backing of an alginate dressing.It is thus another salient advantage of the patent described herein that the dried alginate foam composition, when ready to be cut into appropriate sized dressings, packaged, and sterilized ready for use, already has a backing affixed to the alginate foam composition and does not require any additional secondary sterile backing after the alginate composition is placed on an open wound.EXAMPLE 2 Add 1200 ml of the 2.5% sodium alginate HV brand as prepared above in Example 1 to a 4 liter beaker and with vigorous stirring add the following ingredients in the following order.ml of ammonium hydroxide, 12 ml of Tween 80, 12 ml of L64, grams of sodium bicarbonate, grams of ammonium alginate (SuperloidR brand of 11 Kelco Co.Add 700 ml of deionized or distilled water and when all of the ingredients have been thoroughly mixed, add 15 grams of sodium tetraborate dissolved in 150 ml of water. With continuous stirring, now slowly add 5 grams of calcium sulfate, 110 ml of glycerin, and stir for approximately ten minutes. Add 30 ml of dilute acetic acid, the addition of which and the preparation of which are as described in Example 1 above and then the composition may be layered onto a surface or onto a suitable backing, and dried, as described in Example 1 above.EXAMPLE 3 The zinc salt of bacitracin, having a concentration of 67 IWmg, is added in an amount of 230 mg to 10 ml of deionized water. Neomycin sulphate powder assaying as 704 mcg neomycin/mg of antibiotic is added to 10 ml of deionized water in an amount of 135 mg. Polymyxin B sulphate containing 8547 units of polymyxin B/mg of powder is added to 10 ml of deionized water in an amount of 22.6 mg. The three separate solutions are stirred until all of the antibiotics have been dissolved. Antibiotic solutions thus prepared are added to 1200 ml of the 2.5% solution of sodium alginate Kelco brand HV and with continuous and vigorous stirring, the rest of the ingredients as set forth in Example 1 and in the 12 concentrations utilized in Example 1 are added to the alginate-antibiotic composition which may then be may be spread and dried as described in Example 1 above.EXAMPLE 4 To 1200 ml of a 2.5% sodium alginate preparation prepared as in Example 1 above, add the following ingredients in the following order:grams of sodium bicarbonate ml of glycerin 6.9 ml of the surface active agent L64 6.9m1 of the surface active agent Tween 80 After stirring vigorously for approximately 10 minutes to ensure that all of the ingredients have been dispersed, add 150 mI of deionized water containing 50 grams of sodium tetraborate. After stirring for a few minutes to ensure that the borate solution has been thoroughly dispersed, add 60 ml of ammonium hydroxide and 75 ml of glycerin.While continuously stirring, slowly add 1 gram of calcium sulfate into the vortex of the solution and then follow with 20 ml of a dilute solution of acetic acid prepared by diluting one part of glacial acetic acid with 2 parts of deionized water.The diluted acetic acid should be added very slowly with a pipette, again into the vortex of the stirred mixture, and vigorous stirring continued for approximately five minutes.13 Following the addition of the acetic acid, the composition will gradually become more viscous, one should continue to add 1000 ml of deionized water. With stirring continued, add 1 gram of a highly -5 hydrophilic preparation called "Drimop"R as manufactured by Multisorb Technologies.The "Drimop" preparation is highly hydrophilic and therefore, a n amount of water would be retained by this product, even after drying in accord with the process set forth in Example 1.The unique value of adding a small amount of this highly hydrophilic preparation results in the retention of bound water to the "Drimop" which results in a dressing having an amount of moisture which retains a -cool' touch when the dressing is applied to an open wound. The "Drimop", being highly hydrophilic, also enhances the moisture-absorbing capacity of the dressing when it is applied to an open and/or exudating wound.The alginate composition thus prepared may be spread on a flat surface and/or onto a suitable backing as described in Example 1 above and air- or oven-dried, again as described in Example 1.EXAMPLE 5 An alginate foam composition is prepared as described in Example 1 above. The alginate may then be sterilized in a suitable container by ionizing or 14 other suitable sterilizing radiation.Using established aseptic techniques, a cell suspension is prepared from a culture of human, animal, or microbial cells and are aseptically 5 harvested in a suitable buffered medium.The cells thus suspended in a medium are then added aseptically to the sterile alginate foam slurry, as prepared above, with slow mixing.The cell containing alginate foam slurry can then aseptically be layered onto a sterile sheet so that when dried, may be cut into appropriate sizes as required.EXAMPLE 6 A 600 ml quantity of 2.5% sodium alginate as prepared above in Example 1 is added to a 4 liter container, and to the alginate is added the following ingredients in the following order:ml of glycerin ml of deionized water 6 ml of Tween 80 6 ml of L64 surface active agent 8 grams of sodium bicarbonate 7.5 grams of ammonium alginate (as sold under the trade name of SuperloidR manufactured by Kelco Corporation) With continued and vigorous stirring, add 1.0 grams of calcium sulphate, and 50 grams of maltodextrin with a dextrose equivalent of 13.0 to 17.0 as prepared by Aldrich Chemical Company, Inc.The ingredients are stirred vigorously with a stirrer until the composition becomes viscous and to this composition is added 20 ml of ammonium hydroxide and 150 ml of deionized water.Dilute acetic acid prepared as described above in Example 1, is slowly added with a pipette to a total amount of 11.0 ml. The dilute acetic acid will react with the sodium bicarbonate and form a foam which remains intact in the semi-solid composition which can be continuously stirred until it is ready to pour onto the surface of a plate where it can be dried at room temperature or in an oven as described in Example 1.Alternatively, the composition can be layered onto a gauze, cotton, or polyester backing where, when dry, it will adhere to and become affixed to the fibers of the backing. The dried finished dressing can be cut, packaged into suitable packages as is well known in the profession and sterilized and stored in hospital settings to be used when required.The alginate component in contact with an open wound will gradually become hydrocolloidal and permit the continuous diffusion of the maltodextrin to the site of the wound and will retain all of the clinical advantages that are delineated in U.S. Patent Numbers 5,177,065 and 4,778,679 as well as in the literature 16 of DeRoyal for its Multidex brand of maltodextrin wound dressing.EXAMPLE 7 The ingredients that are described in Example 6 above are prepared in the same way and to the semisolid composition is added 0.5 grams of ascorbic acid, to provide the beneficial effect of ascorbic acid as it is described in the U.S. Patents 5,177,065 and 4,778, 679 and in the literature of DeRoyal for its Multidex brand of maltodextrin wound dressing.EXAMPLE 8 The alginate composition as described in Example 1, is prepared with stirring and to this alginate composition is added a dispersion of 10.0 ml of bovine collagen.This composition can now be dried and layered with or without a backing as described in Example 1.The above descriptions and examples illustrate particular constructions including the preferred embodiments of the solutions. However, the invention is not limited to the precise constructions described herein, but, rather, all modifications and improvements thereof encompassed within the scope of the invention.The sodium alginate principally utilized in the examples described herein was one having an aqueous viscosity of 753 cP at 1.25% concentration. It is 17 clear that other sodium alginates having other viscosities may be utilized without deviating from the novelty of the revelations contained in this patent as long as the alginate is of a concentration and viscosity that can be reasonably poured into a mold when a calcium or other anion alginate precipitating molecule is added to the sodium alginate.Although the alginate used in the examples described herein was sodium alginate, it is clear that other water soluble alginates may be utilized without deviating from the novelty of the invention described herein such as water soluble ammonium alginate, magnesium alginate, or potassium alginate.It is well known in the profession that various glycols will act as plasticizers and may be used to improve the flexibility of alginate films or fibers. The plasticizer that we have principally used in the examples described herein has been glycerin because of its low cost and ready availability. It is clear however that other plasticizers may be utilized such as propylene glycol or ethylene glycol without deviating from the novelty of the invention described herein.In the examples cited herein, calcium chloride has been utilized to provide the calcium ion which precipitates the insoluble calcium alginate which serves to entrap into the calcium alginate matrix other components as described herein. It is clear, as has been mentioned, that other salts may be utilized to precipitate the alginate such as those of aluminum, zinc, copper, chromium, or silver and these insoluble alginates may readily be utilized to precipitate the coercive alginate mixtures described in the Examples provided herein without deviating from the essential merits of this invention. However, since the alginate compositions are to be utilized in and on biological tissues, the particular salt utilized to precipitate the alginate should be dictated by any restraints of toxicity or other untoward reactions that might result from their use for the preparation of bandages, dressings, or surgical products as herein described.Note that in Example 8, we utilized bovine collagen as a component in the alginate mixture so that the insoluble calcium alginate gel will contain an agent which has hemostatic activity, and therefore would serve to stem the flow of blood from a wound when a dressing containing collagen is placed thereon. However, it is clear that other collagens such as porcine collagen may be incorporated into the alginate composition without deviating from the essential merits of this invention.Note that in Example 3 we incorporate antibiotics into the alginate composition. Other medicinal agents 19 which may be desirable in the treatment of wounds such as anti- inflammatory agents or antibacterial agents, can be incorporated into the alginate mixture without deviating from the novelty of the invention described herein.Many of the examples described herein utilize the surface active agents such as those characterized as Tween 80 or Pluronic L64. These surfaceactive agents are utilized primarily to effect a dispersion between the non-aqueous miscible components utilized in achieving a coercive mixture with the aqueous soluble sodium alginate in order to insure a homogeneity throughout the solutions that are then precipitated as insoluble alginate compositions.Is These surface active agents are also utilized in order to improve the wetting of a medical dressing or bandage in the event that a wound may be exudating, and the enhanced wicking in such a bandage or medical dressing serves to quickly absorb any blood or serum from a wound into the dressing. Other surface active agents, such as the Na salt of dodecyl S04 (sodium lauryl sulfate) or a member of the group of Tweens (Tween 20, Tween 40, Tween 80, or Tween 85) may be incorporated into the alginate composition without deviating from the novelty of the invention described herein.Note that in the examples cited herein, the effervescent compound that reacts with the water soluble dilute acetic acid with the resultant evolution of gases which become entrapped in the formation of the gel network is sodium bicarbonate.Other water soluble effervescent compounds may be utilized and other acids may be utilized to produce the evolution of gases which become entrapped in the alginate gel network without deviating from the novelty of the invention described herein. Thus, various water insoluble metal salts that can react with water soluble acids are calcium carbonate, calcium phosphate dibasic, barium carbonate, or zinc carbonate. Examples of suitable acids would include acetic acid, lactic acid, maleic acid, gluconic acid, and ascorbic acids.Should it be desirable to utilize gases other than carbon dioxide to form the foam that forms the stable hydrogel composition described herein, inert gases such as nitrogen or argon, or other gases may be directly introduced into the alginate composition described in the claims herein as long as the alginatel compositions described have a viscosity greater than the buoyancy of the gases entrapped therein. The addition of such other gases will cause the formation of stable hydrogel alginate foam compositions in accord with the novelty of the invention described herein.21 Note that in Example 4, we introduce a hydrophilic chemical called "DriMop" for the purpose of enhancing the moisture-absorbing capacity of the dressing. Other hydrophilic compounds may be utilized in order to achieve an enhanced moisture absorption of the dressing without deviating from the novelty of the invention described herein.Example 6 described herein incorporates a maltodextrin chemical within the alginate foam composition having a dextrose equivalent of 13.0 17.0. It is clear that other maltodextrins having dextrose equivalents other than 13.0 - 17.0 such as those which are available having dextrose equivalents of 4.0 - 7. 0 and 16.5 - 19.5, may be utilized within the scope of the invention described herein without deviating from the novelty of the invention herein described.The above descriptions and examples illustrate particular constructions including the preferred embodiments of the solutions. However, the invention is not limited to the precise constructions described herein, but, rather, all modifications and improvements thereof encompassed within the scope of the invention.22 CLAIMS 1. A process for making a water-insoluble alginate sponge or foam product to be utilized in the preparation of wound dressings or surgical products comprising the steps of:(I) mixing together to form a composite liquid mixture (a) an aqueous solution of a water soluble alginate composition; (II) while allowing the total composition of (I) to be mixed, add a di- or trivalent cation metal ion capable of complexing the water-soluble alginate to form water-insoluble alginate hydrogels; (111) adding into the mixture (II) a gaseous foam-forming or effervescent compound(s) and a watersoluble acid and, (IV) pouring said composite mixture into a dish or a tray which is permitted to stand until the water component of the mixture has evaporated.The process of claim 1 wherein said water-soluble alginate is selected from a group consisting of ammonium, magnesium, potassium, and sodium salts of alginate or mixtures thereof.3, The process of claim 1 wherein said polyvalent cation is selected from a metal ion derived from salts selected from the group consisting of alkaline earth 23 metal salts, alkali metal salts, transition metal salts, and mixtures thereof.4. The process of claim 1 wherein said cation is selected from the group consisting of calcium, barium, copper, magnesium, iron, zinc, aluminum, manganese, strontium, and mixtures thereof.5. The process of claim 1 wherein the said effervescent compound is selected from group consisting of the alkali metal carbonates.6. The process of claim 5'wherein said effervescent compound is sodium carbonate.7. The process of claim 5 wherein said effervescent compound is sodium bicarbonate.8. The process of claim 1 wherein said water- soluble acid is selected from the group consisting of acetic, lactic, malic, gluconic, and ascorbic acids.9. The process of claim 1 wherein a medicament is added to the alginate foam composition.10. The process of claim 9 wherein said medicament is selected from the group consisting of collagen, maltodextrin, antibiotics, antibacterial agents, anti-inflammatory agents, ascorbic acid, amino acids, and mixtures thereof.11. The process of claim 1 wherein Natetraborate is added to the alginate foam composition.12. The process of claim 1 where Ca S04 is added to the alginate foam composition.24 13. The process of claim 1 wherein a plasticizer is added to the foam composition.14. The process of claim 13 wherein said plasticizer is selected from a group consisting of glycerin, propylene glycol, ethylene glycol, and polyethylene glycol or mixtures thereof.15. The process of claim 1 wherein a surface active agent is added to the alginate foam composition.16. The process of claim 15 wherein said surface active agent is selected from a group consisting of Tween 20, Tween 40, Tween 80, Tween 85, sodium lauryl sulphate, pluronic L64, or a mixture thereof.17. The process of claim 1 wherein a hydrophilic agent is added to the alginate foam composition.18. The process of claim 17 wherein the hydrophilic agent is the product called "DriMop" as manufactured by Multisorb Technologies.19. The process of claim 1 wherein the foaming is produced by introducing a gas into the alginate composition.20. The process of claim 19 where said gas producing the foam is selected from a group consisting of nitrogen, carbon dioxide, air, argon, neon, or mixtures thereof.21. The process of claim 1 wherein the alginate mixture is poured onto a cloth layer contained in a tray so that the alginate composition thus penetrates into the cloth and, following drying, the calcium alginate composition is affixed to the cloth.22. The process for making a water-insoluble alginate sponge or foam product to be utilized in the preparation of wound dressings or surgical products comprising the steps of:(I) mixing together to form a composite liquid mixture (a) an aqueous solution of a water-soluble alginate composition, (II) adding to the mixture (I) a plasticizer, a surface active agent, and ammonium hydroxide, (III) while allowing the total composition of (I) and (II) to be mixed, adding a di- or trivalent cation metal ion capable of complexing the water-soluble alginate to form water-insoluble alginate hydrogels; (IV) adding into the mixture (III) a gaseous foam-forming or effervescent compound(s) and a water- soluble acid and, (V) pouring said composite mixture into a dish or a tray which is permitted to stand until the water component of the mixture has evaporated.23. The process of claim 22 wherein said water- soluble alginate is selected from a group consisting of ammonium, magnesium, potassium, and sodium salts of alginate or mixtures thereof.26 24. The process of claim 22 wherein said polyvalent cation is selected from a metal ion derived from salts selected from the group consisting of alkaline earth metal salts, alkali metal salts, 5 transition metal salts, and mixtures thereof.25. The process of claim 22 wherein said cation is selected from the group consisting of calcium, barium, copper, magnesium, iron, zinc, aluminum, manganese, strontium, and mixtures thereof.26. The process of claim 22 wherein the said effervescent compound is selected from group consisting of the alkali metal carbonates.27. The process of claim 26 wherein said effervescent compound is sodium carbonate.28. The process of claim 26 wherein said effervescent compound is sodium bicarbonate.29. The process of claim 22 wherein said water soluble acid is selected from the group consisting of acetic, lactic, malic, gluconic, and ascorbic acids.30. The process of claim 22 wherein a medicament is added to the alginate foam composition.31. The process of claim 30 wherein said medicament is selected from the group consisting of collagen, maltodextrin, antibiotics, antibacterial agents, anti-inflammatory agents, ascorbic acid, amino acids, and mixtures thereof.32. The process of claim 22 wherein Na 27 tetraborate is added to the alginate foam composition.33. The process of claim 22 wherein Ca S04 'S added to the alginate foam composition.34. The process of claim 22 wherein said plasticizer is selected from a group consisting of glycerin, propylene glycol, ethylene glycol, and polyethylene glycol or mixtures thereof.35. The process of claim 22 wherein said surface active agent is selected from a group consisting of Tween 20, Tween.40, Tween 80, Tween 85, sodium lauryl sulphate, pluronic L64, or a mixture thereof.36. The process of claim 22 wherein a hydrophilic agent is added to the alginate foam composition.37. The process of claim 36 wherein the hydrophilic agent is the product called 11Drimop" as manufactured by Multisorb Technologies.38. The process of claim 22 wherein the foaming is produced by introducing a gas into the alginate composition.39. The process of claim 38 where said gas producing the foam is selected from a group consisting of nitrogen, carbon dioxide, air, argon, neon, or mixtures thereof.40. The process of claim 22 wherein the alginate mixture is poured onto a cloth layer contained in a tray so that the alginate composition thus penetrates 28 into the cloth and, following drying, the calcium alginate composition is affixed to the cloth.41. A process for making a water-insoluble alginate sponge or foam product to be utilized in the preparation of wound dressings or surgical products comprising the steps of:(I) mixing together to form a composite liquid mixture (a) an aqueous solution of a water soluble alginate composition; (II) adding to the mixture (I) a plasticizer and a surface active agent, (III) while allowing the total composition of (I) and (II) to be mixed, adding a di- or trivalent cation metal ion capable of complexing the water-soluble alginate to form water-insoluble alginate hydrogels; (IV) adding into the mixture (III) a gaseous foam-forming or effervescent compound(s) and a watersoluble acid and, 20 (V) sterilizing the water-insoluble alginate sponge or foam preparation as prepared above and adding to it aseptically a viable cell suspension, and, (VI) aseptically pouring said composite mixture into a dish or tray which is permitted to stand until the water component of the mixture has evaporated.42. The process of claim 41 wherein said viable 29 cellular suspension is selected from a group consisting of human cells, animal cells, microbial cells, or mixtures thereof. 43. The process of claim 41 wherein said water- soluble alginate isselected from a group consisting of ammonium, magnesium, potassium, and sodium salts of alginate or mixtures thereof.44. The process of claim 41 wherein said polyvalent cation is selected from a metal ion derived from salts selected from the group consisting of alkaline earth metal salts, alkali metal salts, transition metal salts, and mixtures thereof.45. The process of claim 41 wherein said cation is selected from the group consisting of calcium, barium, copper, magnesium, iron, zinc, aluminum, manganese, strontium, and mixtures thereof. 46. The process of claim 41 wherein the said effervescent compound is selected from group consisting of the alkali metal carbonates. 20 47. The process of claim 46 wherein said effervescent compound is sodium carbonate. 48. The process of claim 46 wherein said effervescent compound is sodium bicarbonate. 49. The process of claim 41 wherein said water- soluble acid is selected from the group consisting of acetic, lactic, malic, gluconic, and ascorbic acids.50. The process of claim 41 wherein a medicament is added to the alginate foam composition.51. The process of claim 50 wherein said medicament is selected from the group consisting of collagen, maltodextrin, antibiotics, antibacterial agents, anti-inflammatory agents, ascorbic acid, amino acids, and mixtures thereof.52. The process of claim 41 wherein Na tetraborate is added to the alginate foam composition.53. The process of claim 41 wherein Ca S04 'S added to the alginate foam composition.54. The process of claim 41 wherein said plasticizer is selected from a group consisting of glycerin, propylene glycol, ethylene glycol, and polyethylene glycol or mixtures thereof.55. The process of claim 41 wherein said plasticizer is selected from a group consisting of glycerin, propylene glycol, ethylene glycol, and polyethylene glycol or mixtures thereof.56. The process of claim 41 wherein said surface active agent is selected from a group consisting of Tween 20, Tween 40, Tween 80, Tween 85, sodium lauryl sulphate, pluronic L64, or a mixture thereof.57. The process of claim 41 wherein a hydrophilic agent is added to the alginate foam composition.58. The process of claim 57 wherein the hydrophilic agent is the product called "Drimop,' as 31 manufactured by Multisorb Technologies.59. The process of claim 41 wherein the foaming is produced by introducing a gas into the alginate composition.60. The process of claim 59 where said gas producing the foam is selected from a group consisting of nitrogen, carbon dioxide, air, argon, neon, or mixtures thereof.61. The process of claim 41 wherein the alginate mixture is poured onto a cloth layer con tained in a trayso that the alginate composition thus penetrates into the cloth and, following drying, the calcium alginate composition is affixed to the cloth.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/676,670 US7128929B1 (en) | 1999-04-29 | 2000-10-02 | Alginate foam compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30122899A | 1999-04-29 | 1999-04-29 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB9924266D0 GB9924266D0 (en) | 1999-12-15 |
| GB2357765A true GB2357765A (en) | 2001-07-04 |
| GB2357765B GB2357765B (en) | 2004-04-21 |
Family
ID=23162495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9924266A Expired - Lifetime GB2357765B (en) | 1999-04-29 | 1999-10-13 | Alginate foam compositions |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2357765B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7671101B2 (en) | 2003-09-08 | 2010-03-02 | Fmc Biopolymer As | Gelled biopolymer based foam |
| EP2270082A1 (en) | 2004-05-21 | 2011-01-05 | Dr. Suwelack Skin & Health Care AG | Method for producing alginate-containing porous mouldings |
| CN104474574A (en) * | 2014-11-28 | 2015-04-01 | 陕西佰傲再生医学有限公司 | Method and device for preparing dressing for repairing skin wounds |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9456860B2 (en) | 2006-03-14 | 2016-10-04 | Kci Licensing, Inc. | Bioresorbable foaming tissue dressing |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994000512A1 (en) * | 1992-06-19 | 1994-01-06 | Albany International Corp. | Method of producing polysaccharide foams |
| WO1995012632A2 (en) * | 1993-11-04 | 1995-05-11 | Alliedsignal Inc. | Low density materials having good compression strength and articles formed therefrom |
| EP0747420A1 (en) * | 1995-06-07 | 1996-12-11 | Albany International Research Company | Method of producing polysaccharide foams |
-
1999
- 1999-10-13 GB GB9924266A patent/GB2357765B/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994000512A1 (en) * | 1992-06-19 | 1994-01-06 | Albany International Corp. | Method of producing polysaccharide foams |
| WO1995012632A2 (en) * | 1993-11-04 | 1995-05-11 | Alliedsignal Inc. | Low density materials having good compression strength and articles formed therefrom |
| EP0747420A1 (en) * | 1995-06-07 | 1996-12-11 | Albany International Research Company | Method of producing polysaccharide foams |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7671101B2 (en) | 2003-09-08 | 2010-03-02 | Fmc Biopolymer As | Gelled biopolymer based foam |
| US7671102B2 (en) | 2003-09-08 | 2010-03-02 | Fmc Biopolymer As | Gelled biopolymer based foam |
| US7671100B2 (en) | 2003-09-08 | 2010-03-02 | Fmc Biopolymer As | Gelled biopolymer based foam |
| US7674837B2 (en) | 2003-09-08 | 2010-03-09 | Fmc Biopolymer As | Gelled biopolymer based foam |
| EP2270082A1 (en) | 2004-05-21 | 2011-01-05 | Dr. Suwelack Skin & Health Care AG | Method for producing alginate-containing porous mouldings |
| US7998379B2 (en) | 2004-05-21 | 2011-08-16 | Dr. Suwelack Skin & Health Care Ag | Process for the production of porous moulded articles containing alginate |
| CN104474574A (en) * | 2014-11-28 | 2015-04-01 | 陕西佰傲再生医学有限公司 | Method and device for preparing dressing for repairing skin wounds |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9924266D0 (en) | 1999-12-15 |
| GB2357765B (en) | 2004-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6696077B2 (en) | Silver alginate foam compositions | |
| US7128929B1 (en) | Alginate foam compositions | |
| US5718916A (en) | Alginate foam products | |
| AU2012280218B2 (en) | Formulations for wound therapy | |
| EP0994733B1 (en) | A method for preparing a non-fibrous porous material | |
| EP0372966B1 (en) | Hemostatic collagen paste composition | |
| EP1695722B1 (en) | Collagen hemostatic foam | |
| US20030148994A1 (en) | Hemostatic composition | |
| AU2019304254B2 (en) | Hemostatic paste and methods of making thereof | |
| JPH02107267A (en) | Composition for wound filling | |
| JPH04502569A (en) | Gel formulation for wound treatment | |
| TW200418530A (en) | Hemostatic wound dressings and methods of making same | |
| EP2683345A2 (en) | Haemostatic material | |
| MX2012011635A (en) | Hemostatic sponge. | |
| CN105778126A (en) | Genipin cross-linked biogel as well as preparation method and application thereof | |
| KR102683263B1 (en) | hemostatic material | |
| CN101721691A (en) | Preparation for treating and restoring infective wound surface and preparation method thereof | |
| RU2249467C2 (en) | Medicinal material and products based upon this material | |
| US20020142992A1 (en) | Cellulosic foam compositions | |
| WO2004073697A1 (en) | Alginate foam compositions | |
| WO2010062734A1 (en) | Blood coagulation inducing polymer hydrogel | |
| CN114887111B (en) | Bioabsorbable composite hemostatic material and preparation method and application thereof | |
| GB2357765A (en) | Water-insoluble alginate sponge material | |
| JP2022552825A (en) | Compositions that deliver nitric oxide to the skin | |
| RU2322266C2 (en) | Alginate foamy compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 732E | Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977) | ||
| PE20 | Patent expired after termination of 20 years |
Expiry date: 20191012 |